CNS - Alzheimer’s Disease

With the aging of the population, Alzheimer’s disease, or AD, is becoming an increasingly important problem in developed countries throughout the world. For example, according to the Alzheimer’s Association, AD affects approximately 5 million people in the United States and the collective cost of caring for these patients is nearly $150 billion per year. According to Alzheimer Europe, approximately 6 million people in Europe suffer from AD or some other form of dementia. Although there is currently no cure for AD, an early diagnosis of the disease is believed to offer the best opportunity for treatment to improve a patient’s quality of life and slow the progression of the disease. We have discovered a series of biomarkers in urine that could be used to screen patients for AD, providing a potentially useful tool in diagnosing the disease before it reaches an advanced stage. This program is currently in the product development phase, and we are currently identifying a source of samples suitable for verification and clinical development.